Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | EP300 | Q09472 | 3/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.35 |
| ▸ | ACP1 | P24666 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3102783 | 0.93 | HTR2A (0.47) | HTR2AHTR2CHTR2BTLR9TLR8 | |
| SCHEMBL3100113 | 0.87 | EP300 (0.45) | HTR2AHTR2CHTR2BEP300PPARD | |
| SCHEMBL3099656 | 0.79 | HTR2C (0.48) | HTR2AHTR2CHTR2BEP300 | |
| SCHEMBL3098590 | 0.78 | PPARD (0.44) | HTR2AHTR2CHTR2BPPARD | |
| SCHEMBL3099648 | 0.75 | HTR2A (0.45) | HTR2AHTR2CHTR2BPPARD | |
| SCHEMBL3100813 | 0.75 | HTR2A (0.45) | HTR2AHTR2CHTR2BADORA3ADORA1 | |
| SCHEMBL3097379 | 0.75 | HTR2A (0.45) | HTR2AHTR2CHTR2BPPARD | |
| SCHEMBL3092687 | 0.74 | FAAH (0.45) | HTR2AHTR2CHTR2BJAK2JAK1 | |
| SCHEMBL3100353 | 0.74 | MAPK14 (0.44) | HTR2AHTR2CHTR2B | |
| SCHEMBL13157852 | 0.73 | LMNA (0.42) | PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234395-A1 | UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | TORAY INDUSTRIES, INC. (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100234395-A1 | UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | TORAY INDUSTRIES, INC. (JP) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234395-A1 | UREIDE DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | UROD, UTS2R, SLC14A1 | HTR2A 937/4885HTR2C 1142/4885HTR2B 1054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.